CA057-001
A Phase 3, Randomized, Multicenter, Open-Label Study, Comparing CC-92480, Bortezomib and Dexamethasone (480Vd), with Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
Description: This trial compares the effectiveness of 2 combination treatments (CC-92480, Bortezomib and Dexamethasone combination v's Pomalidomide, Bortezomib and Dexamethasone combination ) in patients with Relapsed or Refractory Multiple Myeloma
Study Phase: Phase 3
Principal Investigator: Dr Patrick Hayden
Further information